The Cost Effectiveness of Sacubitril/Valsartan For The Treatment of Chronic Heart Failure With Reduced Ejection Fraction In Korea

Abstract

The quality-adjusted life year (QALY) gained of 0.5646 results in an ICUR of $22,345 for sacubitril /valsartan vs. enalapril. The most influential parameter in univariate sensitivity analysis is the constant term in the statistical model of CV mortality. ConClusions: Sacubitril/valsartan compared with ACEi for HFrEF patients is cost-effective given on a ceiling ratio of $23,000 per LYG in Taiwan. PCV94 Cost-EffECtiVEnEss AnAlysis of iVAbrAdinE in thE trEAtmEnt of PAtiEnts With ChroniC hEArt fAilurE in irAn